Expiration date: 09/2026
Method of administration and dosage
Always take the drug in full accordance with the recommendations of your doctor.
If in doubt, consult your doctor.
Recommended dose
Take 2 tablets 3 times a day. The maximum daily dose is 6 mg.
Special patient groups
Elderly patients
The drug has not been studied in elderly patients.
Patients with impaired renal function
The drug has not been studied in patients with impaired renal function.
Patients with impaired liver function
The drug has not been studied in patients with impaired liver function.
Route and (or) method of administration
Inside, during or after a meal, at approximately the same time. The recommended time interval between meals is 4-6 hours.
Duration of therapy
The recommended course of use is 28 days.
If you forgot to take the drug Rankvilon®
If you forget to take the drug on time, skip this dose and take the next one at
the scheduled time. Do not take a double dose to compensate for a missed dose. Instead, wait for the time of the next drug intake.
If you have any questions about the use of the drug, contact your doctor.
Indications
The drug Rankvilon® is indicated for use in adults over 18 years of age.
Anxiety states in neurasthenia and disorders of adaptive reactions.
Composition
The drug Rankvilon® contains
The active ingredient is N-(6-phenylhexanoyl) amideGlycyl-L-tryptophan.
Each tablet contains 1.00 mg of N-(6-phenylhexanoyl) amideGlycyl-L-tryptophan.
Other ingredients (excipients) are: lactose monohydrate, microcrystalline cellulose, magnesium stearate, croscarmellose sodium.
10 or 15 tablets in a contour cell package or a contour cell package with a perforation of polyvinyl chloride film and aluminum foil printed varnished.
6 contour cell packs of 10 tablets or 4 contour cell packs of 15
the tablets, along with the leaflet, are placed in a pack of cardboard.
Contraindications
Do not take Rankvilon® if you are allergic to the active substance or any other components of the drug listed in section 6 of the leaflet.
The drug Rankvilon® is contraindicated in children and adolescents under the age of 18 years.
Special instructions
Consult your doctor before taking the drug. Be sure to inform us if you have any contraindications listed in the "Contraindications" subsection of this leaflet.
Children and teenagers
Do not give Rankvilon® to children and adolescents from 0 to 18 years of age (safety and efficacy have not been established). The drug Rankvilon® is contraindicated in children and adolescents under the age of 18 years.
The drug Rankvilon® contains lactose
If you have an intolerance to certain sugars, consult your doctor before taking this medicine.
The drug Rankvilon® contains sodium
The drug Rankvilon® contains less than 1 millimole (23 mg) of sodium, that is, in fact, it does not contain sodium.
Packaging and release form
Tablets of 1 mg - 60 pieces together with a leaflet in the package.
Side effects
Like all medications, the drug can cause undesirable reactions, but they do not occur in everyone.
The most serious adverse reactions
The most serious adverse reactions include reversible deterioration of acuity.
vision (the frequency is unknown - based on the available data, the frequency of occurrence cannot be determined). Stop taking Rankvilon® and inform
your doctor immediately if you experience visual disturbances.
Other possible adverse reactions that may occur when taking
Rankvilon®
The following adverse reactions have been reported in clinical trials of Rankvilon®:
The frequency is unknown - based on the available data, the frequency of occurrence cannot be determined:
irritability;
tendency to daydream, daydreaming (daydreaming);
Mood swings (affective lability);
insomnia;
sleep disorders;
sleep disorder;
drowsiness;
daytime sleepiness;
headache;
dizziness;
increased drowsiness (somnolence);
tremors in various parts of the body caused by muscle contraction (tremor);
taste disorders, manifested as a persistent metallic or sour
taste in the mouth, as well as a burning sensation (dysgeusia);
attention disorder;
nausea;
diarrhea;
joint pain (arthralgia);
the appearance of protein in the urine, detected by laboratory tests (proteinuria);
feeling of general weakness (asthenia).
Reporting of adverse reactions
If you experience any adverse reactions, consult your doctor.
This recommendation applies to any possible adverse reactions, including
including those not listed in the leaflet. You can also report adverse reactions to the information database on adverse reactions (actions) to medicines, including reports on the ineffectiveness of medicines detected in the territory of a Member State. By reporting adverse reactions, you are helping to gain more information about the safety of the drug.
Pharmacotherapeutic group
of psycholeptics; anxiolytic agents; other anxiolytic agents
Interaction with other medicinal products
Tell your doctor that you are taking or have recently taken, or may start taking any other medications.
Influence on the ability to drive a car and other mechanisms
The effect on the ability to drive vehicles and work with mechanisms has not been studied, however, given the mechanism of action and the profile of possible adverse reactions, it can be assumed that the drug has a moderate effect on the ability to drive vehicles and work with mechanisms.
The drug may cause undesirable reactions that make it difficult to concentrate and react quickly,
such as drowsiness and dizziness.
During the treatment period, it is necessary to refrain from driving vehicles and working with mechanisms.
Use during pregnancy and lactation
There are no data on the use of Rankvilon® in pregnant women. The use of the drug during pregnancy is contraindicated. At the onset of pregnancy, the drug should be discontinued.
It is not known whether the drug Rankvilon® penetrates into breast milk.
The use of the drug during breastfeeding is contraindicated.
If it is necessary to take the drug
during lactation, breastfeeding should be discontinued for the duration of treatment.
Pharmacodynamics
What is the drug Rankvilon®, and what is it used for?
The drug Rankvilon® contains the active ingredient N-(6-phenylhexanoyl) amideGlycyl-tryptophan. It belongs to a group of drugs called "psycholeptics; anxiolytic agents; other anxiolytic agents".
The method of action of the drug Rankvilon®
The drug Rankvilon® eliminates the feeling of anxiety and fear (the mental component of anxiety) and related painful conditions and sensations at the level of various
body systems (somatic and autonomic symptoms of anxiety), as well as irritability and
anxiety-related disturbances of nighttime sleep and mental (cognitive) functions. It does not affect muscle tone and motor activity (it does not have
a muscle relaxant effect). When taking the drug Rankvilon®, drug dependence does not form and withdrawal syndrome does not develop.
If there is no improvement or you feel worse after 28 days, you should
consult a doctor.
Storage temperature
from 2℃ to 25℃
Dosage form
Round flat-cylindrical tablets of white or almost white color with a chamfer.
Overdose
If you have taken Rankvilon® more than you should have
No cases of overdose of Rankvilon have been reported to date. In case of overdose, contact your doctor, you may need treatment depending on your condition and symptoms.
